Nonprofit hospitals creating new generic drug company

Intermountain Healthcare, Ascension Health, SSM Health and Trinity Health announced they’ll create their own not-for-profit generic drug company, called Project RX, with the goal of increasing pharmaceutical competition and making “essential generic medications more available and more affordable.”

The systems, which combined control about 300 hospitals in the U.S., said other hospital groups may join the initiative. The U.S. Department of Veterans Affairs is also involved and may become a purchaser once Project RX is up and running.

“It’s an ambitious plan, but healthcare systems are in the best position to fix the problems in the generic drug market,” Intermountain president and CEO Marc Harrison, MD, said in a statement. "We witness, on a daily basis, how shortages of essential generic medications or egregious cost increases for those same drugs affect our patients. We are confident we can improve the situation for our patients by bringing much needed competition to the generic drug market.”

The new venture will have plenty of customers “ready and eager for its products” within the health systems themselves. By making the supply of generics more predictable, the companies said it can counter current manufacturers’ “unwarranted and arbitrary price increases” and creation of artificial shortages of medications.

An advisory committee will help guide the new company, with members including former CMS Administrator Don Berwick, MD, and former Nebraska Gov. and U.S. Senator Bob Kerrey.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup